Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results
Date:11/3/2008

al dryness,

over other treatments. The Company expects to begin human clinical

trials for VG101 late in 2008 or early in 2009.

"The third quarter of the year continued the positive scientific progress for Bionovo," said Dr. Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "After much preparation and discussion with the FDA and our advisors, we are now poised to begin the next phase of clinical testing for our portfolio of women's health and oncology drug candidates. We are also continuing promising discussions with potential pharmaceutical partners."

"With over seventeen million dollars in cash, cash equivalents and short- term investments, and a lower than industry clinical trial cost profile, we are poised to progress our lead drug candidates through these challenging economic times," added Tom Chesterman, Bionovo's Senior Vice President and Chief Financial Officer. "Given our current plans and expectations, this funding will be sufficient for at least the next 12 months"

A full financial report on Form 10-Q is expected to be filed by Tuesday, November 4, 2008.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.b
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... 2014 Your cell phone may ... lithium-ion battery storage capacity. , New research indicates ... model created at Lawrence Livermore National Laboratory ... how carbon components will perform as electrodes. , ... urgent need for higher-performance batteries. Several key characteristics ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) -- ... and monetization of intellectual property, today announced that the ... ending June 30, 2014 on Monday, August 18, 2014 ... 10 a.m. ET on Monday, August 18, 2014 to ... by the company,s CEO, Anthony Hayes . ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... an agreement-in-principle to ensure the valorization and the operation under ... Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for human ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de Montreal ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ... pharmaceuticals in China, today reported,unaudited financial results for the quarter ... -- Total revenue increased to RMB442.5 million ... first quarter of 2009 from RMB394.6 million for the corresponding, ...
Cached Biology Technology:Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire-iReach/ -- ... managing data from cardiac devices, has cut emergency room ... the UC San Diego (UCSD) Medical Center, according to ... Journal. The UCSD Emergency Departments are using the suite ... such as pacemakers or defibrillators. "Using Geneva,s ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... documents dating back 3,500 years say they have found ... ancient Egypt and not with Hippocrates and the Greeks. ... Biomedical Egyptology at The University of Manchester discovered the ... before Hippocrates was born. , "Classical scholars have ...
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... Investigator, and Nancy Bae, Ph.D., Postdoctoral Research Associate ... offering insight into the way cells protect chromosome ... tomorrow's issue of Molecular Cell, their paper entitled ... Human Telomeric DNA Ends" employed a biochemical assay ...
Cached Biology News:Egyptians, not Greeks were true fathers of medicine 2Double the death rate from cirrhosis for 'blue collar' men 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: